BTK and neoplasm: This preclinical study demonstrated differential binding of pirtobrutinib to both BTK and BTKC481 substitution mutants that prevented BTKY551 phosphorylation in the activation loop and inhibited BTK signaling in multiple B cell lymphoma cell lines and lymphoma xenograft tumor growth [22].